.jpg/jcr:content.webp)
Vaccines
Science in Vaccines
Beyfortus®: Made with All Infants in Mind to Protect Against RSV
Up to 75% of RSV-associated hospitalisations occur in healthy and full-term children.2 Recent studies have shown that nirsevimab provided up to 90% protection against hospitalisation from severe RSV LRTI in infants during their first RSV season.3
Understanding RSV: Disease Burden and Nirsevimab’s Efficacy
In Singapore, RSV circulates all-year round and causes significant paediatric health and economic burden.2 This highlights the need and importance of RSV immunisation to reduce the burden of disease.2
RSV Prevention for Every Infant: Favourable Safety Profile
RSV is the primary cause of LRTIs in children worldwide.2 Infants aged 3 months old have the highest risk of severe RSV LRTIs.2
Please log in or register to continue reading.
Request-form
